Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.
Study links higher-potency cannabis use in youth to increased risk of psychotic experiences
Young individuals consuming higher-potency cannabis, such as skunk, between ages 16 and 18, are twice as likely to have psychotic experiences from age 19 to